EGF-L7 human
SIGMA/SRP3319 - recombinant, expressed in E. coli, ≥98% (SDS-PAGE or HPLC), ≥98% (HPLC)
Synonym: MEGF7; Multiple EGF-like domains protein 7
Product Type: Chemical
Epidermal
Growth Factor Receptor (EGFR) Pathway Research areas:
Cancer biology, Cell proliferation, Metabolism. Disease areas:
Breast, lung, stomach, gastrointestinal cancers, chronic kidney diseases,
glioblastomas.
| assay | ≥98% (HPLC) |
| ≥98% (SDS-PAGE or HPLC) | |
| biological source | human |
| form | lyophilized |
| impurities | endotoxin, tested |
| mol wt | 28.0 kDa |
| packaging | pkg of 10 μg |
| recombinant | expressed in E. coli |
| shipped in | wet ice |
| storage temp. | −20°C |
| UniProt accession no. | Q9UHF1   |
| Biochem/physiol Actions: | EGF-L7 (Epidermal Growth Factor Like Protein 7, Multiple EGF Like Domains Protein 7, VE Statin) is a multi-domain protein containing two EGF like domains and one EMI domain. Recombinant human EGF-L7 is a 28 kDa protein containing 251 amino acid residues. |
| General description: | EGF-L7 (Epidermal Growth Factor Like Protein 7, Multiple EGF Like Domains Protein 7, VE Statin) is a multi-domain protein containing two EGF like domains and one EMI domain. It is expressed almost exclusively in endothelial cells and functions to promote normal development of the vascular system, particularly tubulogenesis. EGF-L7 is capable of antagonistic binding to Notch receptors resulting in the inhibition of Notch signaling in HUVEC and neural stem cells. In research models inducing hypoxia and subsequent reoxygenation, (H/R), EGF-L7 can inhibit ICAM-1 expression and enhance the inhibition of NF-kappaB activation. Additionally, EGF-L7 can chemoattract endothelial cells and bind to the extracellular matrix. The overexpression of EGF-L7 is observed in various cancers, and is generally correlated with increased metastasis and a poor prognosis. Recombinant human EGF-L7 is a 28 kDa protein containing 251 amino acid residues. |
| Physical form: | Lyophilized with no additives. |
| Preparation Note: | Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC); ≥98% (SDS-PAGE or HPLC) |
| Storage Temp. | −20°C |
| UNSPSC | 12352202 |